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Abstract 
The use of artificial intelligence will likely transform clinical practice over the next 
decade and the early impact of this will likely be the integration of image analysis and 
machine learning into routine histopathology. In the UK and around the world, a digital 
revolution is transforming the reporting practice of diagnostic histopathology and this 
has sparked a proliferation of image analysis software tools. While this is an exciting 
development that could discover novel predictive clinical information and potentially 
address international pathology work-force shortages, there is a clear need for a 
robust and evidence-based framework in which to develop these new tools in a 
collaborative manner that meets regulatory approval. With these issues in mind, the 
NCRI Cellular Molecular Pathology (CM-Path) initiative and the British in vitro 
Diagnostics Association (BIVDA) has set out a roadmap to help academia, industry 
and clinicians develop new software tools to the point of approved clinical use. 
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Introduction 
The integration of artificial intelligence (AI) will be one of the biggest transformations 
for medicine in the next decade and histopathology is right at the centre of this 
revolution. The value, both for medical practice and creating business and wealth from 
AI has been recognised across the world and in particular by the UK Government who 
published an Industrial Life Sciences Strategy in August 2017 [[1]. Histopathology was 
highlighted in the report as ‘’being ripe for innovation’’ and ‘’where modern tools should 
allow digital images to replace the manual approach based on microscopy’’ in addition 
to ‘’the opportunity to create AI-based algorithms that could provide grading of tumours 
and prognostic insights that are not currently available through conventional 
methodology’’.  
 
Much of the workflow of histopathology departments remains largely unchanged for 
decades, although some processes can be automated e.g. immunohistochemistry and 
more recently routine molecular testing has been incorporated for some disease types. 
The adoption of digital pathology (DP) technologies to replace microscopy has been 
slow and adoption of the use of image analysis/AI tools to augment the workflow or 
solve capacity issues is limited. Algorithms have the potential to either perform routine 
tasks which are currently undertaken by pathologists, or provide new insights into 
disease, which are not possible by a human observer [2]. 
 
Innovate UK recently awarded £50M to create five new centres of excellence for DP 
and imaging using AI medical advances [3]. The centres will aim to realise the benefits 
of AI in pathology by speeding up diagnosis, improving outcomes, providing better 
value for money and allowing clinicians to spend time on other tasks. The vision is a 
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healthcare service which transforms the NHS into an ecosystem of enterprise and 
innovation that allows technology to flourish and evolve. Two of the five centres focus 
entirely on DP AI, with a third centre focussing on imaging and DP. These new DP 
centres are known as PathLAKE, a DP consortium led by University Hospitals 
Coventry and Warwickshire NHS Trust and also including Oxford, Belfast and 
Nottingham, the Leeds-led Northern Pathology Imaging Co-operative (NPIC) and the 
pan-Scottish iCAIRD (Industrial Centre for AI Research in Digital Diagnostics). Each 
centre was awarded funding in partnership with industry, who will make significant in-
kind investments.  
 
A small number of approved image analysis tools exist, e.g. oestrogen receptor status, 
but their use is not widespread. The barriers to uptake are multifactorial, but 
uncertainty around the accreditation is a significant contributor. In the UK, for example, 
laboratories are strongly encouraged to be assessed by the UK Accreditation Service 
(UKAS) to establish competence in applied-for activities, assessed against ISO 15189 
(2012) [4]. AI tools should be no different. Although quantification tools may assist 
pathologists and reduce the subjectivity of human observers, the notion that AI will 
replace the need for pathologists to make even simple interpretative judgements is 
one that the pathology community struggles with [5]. It is likely that outputs generated 
by such tools will increase the complexity of the information that needs to be 
assimilated into integrated diagnostic reports as part of a modern precision medicine 
driven approach with pathology forming part of the “big data’’ set [6]. 
 
The first major step in adopting DP is the introduction of digital whole slide imaging 
(WSI) into routine practice. This is now well evidence-based and will provide the 
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infrastructure and initial datasets for building AI tools [7-9]. With departments now 
beginning to make the digital transition [10], and in the context of current and near 
future predicted shortages of pathology staff [11,12], the opportunity for computer-
aided diagnosis (CAD) will almost certainly become the real focus of DP research over 
the next 10 to 15 years.  
 
With this in mind, in June 2018 the NCRI Cellular Molecular Pathology Initiative (CM-
Path) [13] joined forces with the British In Vitro Diagnostics Association (BIVDA) [14] 
and organised a workshop with academic, clinical, regulatory and industry leaders to 
look at the use of AI in a clinical histopathology environment. The aim was to 
understand the path from tool concept, through development to full roll-out in a routine 
histopathology workflow, understanding the roadmap and the challenges at each 
stage. The objective was to understand why such tools have had limited uptake thus 
far, in order to understand the barriers before a larger number of products hit the 
market. Understanding the process involved in clinical adoption from concept through 
to clinical practice will enable more confidence in understanding of the steps 
necessary to support appropriate adoption. The different groups present, reflected the 
differing expertise needed to achieve this, with pathologists often holding the clinical 
expertise and cohorts with industry the market expertise. The group was completed 
by regulators and accreditors. Here, we report the output from the workshop, present 
our road map (Figure 1) for developing new tools and outline the components needed 
in AI tool development (Table 1) for clinical use.   
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Potential Applications 
The potential applications of AI in DP are wide ranging, but the focus of interest now 
is largely based around digital image analysis (DIA). Established image analysis 
involves a combination of manual or computer aided image processing techniques 
(such as colour correction, filtering and other basic manipulation methods) and user-
driven feature classification and extraction (e.g. edge detection, pixel intensity 
thresholding, mathematical transformations) based on pre-defined parameters. Newer 
methodologies, often termed artificial intelligence (AI), are based on machine-learning 
algorithms, whereby an automated computer program runs the image analysis and 
uses various statistical methods to model the output data to progressively fit (‘learn’) 
to some defined outcome of interest. For example, this could be the likelihood that a 
specific diagnosis is present in the image, or the likelihood that the tumour in an image 
will respond to chemotherapy. An AI program can be ‘trained’ with example images 
(supervised learning) or the software can be allowed to discover key features that fit 
the outcome for itself (unsupervised learning). In either case, AI tools can be user 
directed (run on demand by pathologists or laboratory staff) or can be completely 
automated and the extent of interaction with an AI tool by the pathologist can vary from 
the user deciding to run a program and evaluating the quality of the output, to simply 
reporting the output from an automated analysis that has run in the background. 
Practical applications may include immunohistochemistry (IHC) biomarker detection 
and scoring (for example, Her-2 and Ki67 tools are already available with many other 
markers in development), disease quantification, morphometrics, tumour detection 
and cancer grading, and rare event screening (e.g. highlighting samples where tumour 
or micrometastases are detected and need pathologist review, and those which are 
negative and may not need review) [15-19].  
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Concept Development 
The first step for DP is the transition from traditional microscopy to digital slides. The 
first stage of creating any new AI application (often called ‘app’ or ‘tool’) however is 
concept development: identifying the clinical need and defining the potential solution. 
Currently, ideas for new tools come from a variety of interested parties including 
industry (biotechnology companies, drug company companion diagnostics), academia 
(academic pathologists, computer scientists, engineers), practicing histopathologists 
and clinical staff (e.g. oncologists) – many of whom are working on similar projects 
and often repeating work being done elsewhere (see Table 1). This is the first major 
challenge – definition of the clinical need and who should be making those decisions 
and setting priorities around algorithm building. Industry and academia often have 
different perspectives on what tools should be developed as different measures of 
success are applied – typically a successful commercial product in industry versus 
grant funding and academic publications. Although most companies solicit specialist 
advice to guide the direction of suitable potential candidate applications for 
development, companies are often pulled in other directions by existing technology 
preferences and platforms, access to technical expertise and resources, and IP in the 
form of patents, technology, know-how, market positioning etc. They are likely to prefer 
to use proprietary technologies at the early stages of development as this is seen as 
the most protectable route to a return on their investment. This may result in a 
disconnect between what is launched commercially and what is actually required by 
the end users of the products in the delivery of the clinical services they provide. In the 
UK, the newly formed network of national AI centres of excellence is expected to be 
pivotal in them bringing the diverse groups of health and academic institutions, 
entrepreneurs and commerce together.  
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Ethics and Funding 
AI tool development must consider the need for Research and Ethics Council (REC) 
approval, which is generally required in the research and trial stages. Developers have 
to comply with the ethics of using patient data for research development, commercial 
gain and return for the NHS. Mindful of the value of patient data for research and the 
challenges of obtaining consent for its use the NHS is establishing the National NHS 
Opt Out Scheme to provide individual patients with some control over what purposes 
their data is used for.  Individual institutions may have in addition local procedures for 
allowing opt out of the use of their data for research and it is important that all of these 
factors are understood and followed in the design stage of AI tool development. There 
are many parallels to be drawn with the therapeutics pipeline; whilst successful 
products will pass through the entire pathway, most likely supported by sequential 
funding rounds from differing sources, many products are bound to fail at some point. 
Measurable outcomes of success are important in enabling rational decisions over 
which products should be supported, and this is relevant to each stage of the pathway, 
up to and including justification of the tool for review and being recommended for use 
in clinical guidelines, e.g. by the National Institute for Health and Care Excellence 
(NICE) in the UK. This typically requires evidence of financial or resource savings, 
improvements in quality, patient impact, and is thus often difficult to prove, particularly 
when the solution involves significant transformation, workflow redesign and financial 
investment.  
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Development 
Once an idea has been conceived and collaboration established, the cycle of tool 
development is a helpful model to understand the process of creating the software. 
This includes defining pre-processing steps (defining the output needed, designing the 
algorithm to obtain this), the analysis stage (pilot or larger follow-up sample), data 
analytics (collection, organisation, storage and processing of raw data, statistical 
analysis of comparison data). This will inevitably require several cycles of trial and 
error to get the tool working well and refining the methodology; this process could be 
thought of being akin to the pre-trial early drug development. There is often a pilot 
stage trial to ascertain if the tool is likely to be of clinical use and there may be some 
overlap with early development and later validation steps. 
 
Validation and Regulation 
The introduction of any new test requires an evidence-based approach to validation 
and this forms a key component of regulation. The new in vitro device regulation 
(IVDR) requirements set out very specific and detailed guidance on validation and we 
summarised our recommendations for a number of key components of validation in 
Table 1. In laboratory medicine there is usually a distinction between a technical or 
analytical validation (the test measures exactly what it is supposed to measure, 
evaluated usually on a deliberately selected population of cases) and a clinical 
evaluation (the test performs well in routine clinical practice, evaluated ideally on an 
unselected and unbiased population of patients) [20], This part of the process could 
be thought of as similar to Phase I (analytical validation) and Phase II/III (clinical 
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validation) drug development. Measures of laboratory and clinical validation should be 
established for any new (index) test against a current gold standard (reference) test.  
In image analysis, an analytical (Phase I) validation is often achieved by comparing a 
tool with so called ‘ground truth’, for example comparing an AI tool count for Ki67 
positive cells on several idealised images compared with a very detailed cell count 
made manually acting as a gold standard. Comparison of any DP technology or 
technique will need to be compared with the performance of Human Pathologists with 
their inherent irreproducibility and day to day performance variation. Defining ground 
truth in this situation is inherently difficult and requires careful study design and an 
acceptance of the weaknesses of the current gold standard reference method. The 
end result must produce a final dataset which can be used to demonstrate (for 
regulatory approval and accreditation) the validity of the app. A clinical (Phase II/III) 
validation involves higher level trials in large patient unselected and blinded datasets. 
An example could be comparing the performance of a Ki67 tool with pathologists in 
assigning a grade to all neuroendocrine tumours that come through a department over 
a set period of time.  
It is likely that for many AI tools it will be difficult to obtain ground truth and there may 
not be any comparable (gold standard) test currently in use by pathologists. In this 
scenario, the validation will primarily be a clinical one and hinge on robust and 
reproducible validations in large patient cohorts with detailed outcome data. One of 
the most pressing issues is the relative lack of such required cohorts for validation. In 
those that exist with mature data, logistical challenges of getting slides scanned are 
often prohibitive. Those who have access to such cohorts are often unwilling to share.   
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Pathologists assessment with an optical microscope is often considered to represent 
the ground truth, and this is a controversial assumption. Interobserver variability and 
subjectivity mean that the observations and annotations of one pathologist should not 
necessarily be considered ground truth. This is especially true when one is building 
tools where the ground truth is subjective e.g. Gleason grading of prostate cancer [21]. 
Validation and testing by multiple pathologists and in multiple laboratories are usually 
required.  
Bringing AI algorithms into diagnostic practice creates interesting new challenges 
around the legal implications of a pathologist signing out a report using AI. The 
pathologist would be required to be confident in the output of the algorithm in order to 
integrate it into the main report and any algorithms used would need to have been 
through appropriate validation and verification. The need for pathologists to build trust 
in new digital systems which may be seen as opaque or “black box” technologies could 
put a natural but important brake on the speed of adoption of AI in digital pathology. 
This could act as a focus for closer collaboration between the industry and end users 
to deliver robust applications that pathologists are happy to rely on when preparing 
and signing out their reports. The fact that AI researchers are now beginning to focus 
on (a) providing confidence estimates with their predictions/results and (b) localising 
pathology-related features should help with allaying concerns about interpretability 
and building trust. Besides, there is also need for regulatory processes to learn from 
the experience of medical imaging community in evaluating the performance of 
algorithms for various challenge contests [22]. The future educational needs of the 
pathology community will change, bringing a need for at least a basic working 
knowledge of how such algorithms function with some pathologists taking on a more 
advanced ‘’computational pathologist’’ role. Similar to many other diagnostic platforms 
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(e.g. molecular diagnostics assays), we suggest that any new AI tool would fall under 
the European Medical Devices Regulation 2002 [23] and are probably best regarded 
as in vitro diagnostic devices (IVD). In the UK currently, the competent authority for 
medical device regulation is  the Medicines and Healthcare Products Regulatory 
Agency (MHRA) and, like elsewhere in the European Economic Area, devices must 
be approved via the conformité Europeéne – in vitro diagnostic device (CE-IVD) 
legislative process (IVD Directive 98/79/EC). For most devices (including WSI imaging 
systems), this has until recently been via the self-certification route. However, there is 
currently a transition phase to the new In-Vitro Diagnostic Medical Devices Regulation 
(2017/746) (IVDR) 11a. Under the new regulations devices are given a risk 
classification (Class A-D), with WSI imaging systems deemed Class C. The IVDR sets 
out a new pathway for certification that will be carried out by approved Notified Bodies 
[24-26]. It is likely that the regulatory changes will continue to apply in UK, after its 
withdrawal from the European Union (EU). The impact of these new regulatory 
changes on development of AI tools is uncertain at this stage, but we recommend that 
all AI tools should undergo CE-IVD marking. This will require additional clinical 
evidence, rigour and assessment by Notified Bodies in addition to existing 
requirements for conformity, including situations where machine learning technology 
is used, and where self-learning systems result in modification to algorithms and data 
analysis workflows that are different from what was originally submitted to gain the 
accreditation in the first place.  
In the US, medical devices are classified based on likely patient risk (Class I-III). Class 
II & III devices (~60% of devices) are required to undergo Premarket Approval (PMA) 
unless there is a specific exemption such as the Humanitarian Device Exemption or 
approval under the Premarket Notification [(510(k)] route for devices which are similar 
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to existing PMA approved devices [7,27]. Previously, the FDA classified WSI imaging 
systems as Class III however in 2017 the FDA classified the Philips IntelliSite 
Pathology Solution (and concurrently by default classified all generic WSI systems) as 
a Class II device (although with special controls) and granted permission for the 
system to be marketed via the [510(k)] route [28]. The route to marketing approval in 
the US may change however. The FDA is piloting a new streamlined approval route 
specifically for digital health products, known as the Software Precertification (Pre-
Cert) Pilot Program. This route would presumably include diagnostic image analysis 
software and AI-based technologies [29]. 
An additional consideration is the use of in-house lab developed methods and tools 
(often called Lab Developed Tests) which in Europe are currently governed and 
controlled under ‘Health Institution Exemption’ to the IVD Directive 11d. These will be 
subject to the new in vitro diagnostic medical device regulation (2017/746) and the 
new medical device regulation (2017/745), in particular, the provisions of Article 5(5) 
of both IVDR and medical devices regulations (MDR). Application of the exemption 
are currently the subject of a consultation exercise by MHRA 11b. Health Institutions 
making or modifying and using a medical device or IVD can be exempt from some of 
the provisions of the regulations provided products meet the relevant General Safety 
and Performance Requirements. Health institutions will need to have an appropriate 
quality management system in place, a justification for applying the exemption and 
technical documentation in place. Some of this information will need to be publicly 
available.  
The development of clinical AI tools by individual institutions will need to conform to 
any new regulations, even if only intended for use within their own institutions. 
However, the benefits and opportunities afforded by DP based systems, on which AI 
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tools depend and run, largely arise from the ability to use them in collaborative 
professional networks over wide areas and between institutions. In pathology, the 
professional norm of collaborating on cases and seeking second opinions will 
increasingly require AI tools to be used in a standardised way between institutions, 
and will require either exemptions to the legislation, or conformance to it that is 
consistent with the emerging DP enabled infrastructure.  
The variability in performance of in-house developed tests is cited as one of the main 
reasons for limiting their use to intra-institution application, and to the move to requiring 
their accreditation and conformance to the new legislation. Tools labelled purely for 
research projects with no medical purpose can be considered for Research Use Only 
(RUO) and exempt from the IVD Directive 11c (devices for performance evaluation 
are subject to the regulation set out above) [30,31]. 
Regulatory advice can be sought from authorities. In the US, this would be the Food 
and Drug Administration (FDA), in the UK this would be the MHRA. The latter 
recommend initial informal enquiries to regulators MHRA can be made via email 
(Innovationoffice@mhra.gov.uk or Devices.Regulatory@mhra.gov.uk). The MHRA 
publishes a variety of guidance documents [25,26], including on medical devices, and 
offers a scientific advice service in the context of medicines development. In addition, 
the Innovation Office provides a free single point of access to expert regulatory 
information, advice and guidance that helps organisations of all backgrounds and 
sizes develop innovative technologies.  
 
Implementation 
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Implementation involves two main areas of focus: test introduction and accreditation. 
To introduce a new test there needs to a be a clinical need, review of the market, 
review of the literature evidence and writing a business case to fund it via healthcare 
budgets. In the case of in-house developed tests, much of this work should have been 
done but when buying in a new CE-IVD marked test, this can be a big undertaking. 
Once a test has been commissioned for use, adhering to accreditation requirements 
for any new tool providing data used in clinical reporting would be encouraged (for 
both in-house and regulatory approved tests). In the UK, this process would be 
provided by the United Kingdom Accreditation Service (UKAS), meeting the 
requirements of  ISO 15189:2012 [32]. All diagnostic laboratory staff will be familiar 
with the usual processes of this (see Figure 1) that include Standard Operating 
Procedure (SOP) documentation, test verification (checking a previously validated test 
is working correctly in your lab by running on a set of known cases), documentation, 
audit cycle, calibration records, non-conformity handling, error and adverse event 
reporting, staff training and participating in External Quality Control (EQA) via a 
scheme such as the UK National EQA Scheme (NEQAS). Any in-house modifications 
to the tool (adjusting user preferences, algorithm tweaks, change of computer 
equipment and screens, change of slide scanners etc.) require each step of the 
accreditation process to be updated and may need to meet the requirements of the 
IVDR health institution exemption. An immediately obvious issue is the need for EQA 
scheme, which currently do not exist, to be up and running – however plans to start 
such a scheme are underway.  
It is beyond the scope of this paper to outline all the working issues of digital pathology 
and this is well covered by others, [15,33] but clearly a major step in the 
implementation of any AI tool in histopathology is the digitization of pathology 
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departments to begin with and until this happens it is unlikely that AI tools will be widely 
adopted. Although this transition will take some time, AI tools could be adopted in 
limited circumstances in the meantime, with individual cases scanned where needed. 
The challenges of course will include issues around financing scanners and software 
and long-term data storage is a problem. The RCPath recommends storage of images 
for at least two laboratory inspection cycles [33] and this requires many terabytes of 
data – often the biggest cost of digitisation a department will face.  
A further major challenge for AI tool development and implementation is platform 
variety, integration and interoperability. In echoes of the early days of 
immunohistochemistry and molecular diagnostics, is the emergence of multiple 
parallel and competing platforms and methodologies, often based on proprietary 
technologies and vendor specific workflows. The health service sector conversely 
requires measurable reliability and interoperability, to enable for example running an 
AI tool from one vendor on another vendor’s platform, and on samples processed in 
separate laboratories. All of these requirements need to be clearly understood and 
addressed in the regulatory process to deliver a useable and standardised routine 
workflow in the laboratory framework. An essential issue is data compatibility and a 
standard, universal file format (that maintains functionality for legacy data) for digital 
WSI has yet to be practically implemented. Although many manufacturers claim that 
their systems are open to other vendors’ file formats, progress is slow and in practice 
there remain many difficulties. Many are now working towards a pathology version of 
the DICOM (Digital Imaging and Communications in Medicine) format and once 
agreed this will need to cope with the adaptations and advancements delivered by 
technological progression.   
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Impact on work force 
The introduction of new technology and tests into clinical practice has an impact on 
the laboratory workflow and the staff (laboratory and pathologist) training. As 
discussed earlier, compliance with UKAS accreditation will require laboratories to 
amend their scope of practice, and assess any tool prior to implementation, measuring 
the observed performance against what is expected (verification). The Innovate UK 
initiative to build a network of UK AI centres will provide an important network of well-
resourced laboratories which will be able to offer leadership and exemplar practices 
for this sector over the coming years.  
Less obvious but no less important is the effect of AI on pathologists and technicians 
using the technology in practice. There is an opportunity for pathologists in particular 
to come to rely too heavily on AI support leading to a degradation of diagnostic ability. 
Individual departments will need to understand how the implementation of such tools 
affects pathologists daily practice in order to understand these risks and provide 
support and assessment to protect and monitor their competence to guard against any 
atrophy of diagnostic skills. The UK Royal College of Pathologists (RCPath) have 
produced guidance on DP in clinical practice [17] but this does not cover the used of 
CADs. Additional work is required to address this emerging gap, which also needs to 
be factored into pathologists’ training. 
 
Conclusions 
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Much of what is discussed here is a distillation of the experiences of those who have 
come from varied background and have been involved in isolated parts of the road 
map. By coming together at the workshop in June, as a group we were able to 
consolidate these ideas and formulate our road map for developing AI software 
applications for use in histopathology practice. We feel strongly that a UK-wide 
strategy should be urgently developed for AI and DP. This technology really offers a 
chance to transform histopathology practice in the face of the extremely challenging 
problems the profession is facing. With proper slide image management software, 
integrated reporting systems, improved scanning speeds and high-quality images, DP 
systems will provide time and cost saving benefits over the traditional microscope 
approach and improve the age-old problem of inter-observer variation. Real and 
significant barriers to this are the introduction of tools without the proper regulatory-
driven, evidence-based validation, the resistance of developers (academic and 
industry) not to collaborate and the need for commercial integration and open-source 
data formats.     
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Table 1. The various tasks that we recommend need to be completed when 
developing and using an AI tool in clinical practice. Regulatory approval in the UK is 
managed by the Medicines and Healthcare Products Regulatory Authority (MHRA), in 
Europe this is done via conformité Europeéne - in vitro diagnostic device (CE marking) 
licensing, and in the US regulation is handled by the Food and Drug Administration 
(FDA). There are new UK regulatory requirements required for IVDR approval – for a 
more detailed description of these, please refer to MRHA publications [25,26], In the 
UK, accreditation is regulated by the UK Accreditation Service (UKAS) and 
management guidelines are compiled by the National Institute for Healthcare 
Excellence (NICE). PPV=positive predictive value, NPV=negative predictive value. 
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Figure 1. The digital pathology AI development ‘road map’. This diagram describes 
the recommended steps in the development of AI and other digital pathology tools for 
use in laboratories. The order of events is given as a guide only and in some 
circumstances flexibility will be needed. In the UK, accreditation is regulated by the UK 
Accreditation Service (UKAS) and management guidelines are compiled by the 
National Institute for Health and Care Excellence (NICE). Regulators in the UK are the 
Medicines and Healthcare Products Regulatory Agency (MHRA), in Europe this is via 
conformité Europeéne - in vitro diagnostic device (CE marking) licensing, and in the 
US, regulation is handled by the Food and Drug Administration (FDA). PPV=positive 
predictive value, NPV=negative predictive value, EQA=external quality control. 
 
 
 
